AbbVie’s RINVOQ shows promise in Vitiligo Phase 3 trials
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
The FW500 is designed to meet the evolving needs of mid-sized diagnostic laboratories
New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents
Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
Subscribe To Our Newsletter & Stay Updated